Results 171 to 180 of about 8,311 (216)
Some of the next articles are maybe not open access.
Radioimmunotherapy for Waldenstrom's macroglobulinemia
Seminars in Oncology, 2003Radioimmunotherapy targeting CD20 is a promising novel treatment for lymphoma. Prior trials have established the safe dose of Zevalin ((90)Y-ibritumomab tiuxetan; IDEC Pharmaceuticals) for patients with no more than 25% bone marrow (BM) involvement. Zevalin is expected to be an effective treatment for WM; however, the safe dose has not been defined.
openaire +2 more sources
Waldenstrom's macroglobulinemia.
The Journal of the Association of Physicians of India, 2005Waldenstrom's macroglobulinemia is an uncommon lymphoplasmacytic lymphoma presenting with hyperviscocity and autoimmune phenomenon. Disease is characterized by bone marrow infiltration by lymphoplasmacytic cells and raised IgM. Bone marrow morphology and immunohistochemistry is important for diagnosis.
N, Singhal +3 more
openaire +1 more source
Waldenstrom macroglobulinemia retinopathy. Waldenstrom and eyes
Journal Français d'Ophtalmologie, 2019openaire +2 more sources
2001
Disease Waldenstrom's macroglobulinemia (corresponding to lymphoplasmacytoid lymphoma / Immunocytoma in the REAL and WHO classification) Phenotype / cell stem origin Stem cell origin: Post-germinal centre IgM-bearing memory B-cell. Phenotype: CD19+; CD20+; CD22+; FMC7+; CD38+; cytoplasmic IgM bright+; CD5-; CD23-; CD10-.
openaire +1 more source
Disease Waldenstrom's macroglobulinemia (corresponding to lymphoplasmacytoid lymphoma / Immunocytoma in the REAL and WHO classification) Phenotype / cell stem origin Stem cell origin: Post-germinal centre IgM-bearing memory B-cell. Phenotype: CD19+; CD20+; CD22+; FMC7+; CD38+; cytoplasmic IgM bright+; CD5-; CD23-; CD10-.
openaire +1 more source
[Waldenstrom's macroglobulinemia].
Vie medicale (Paris, France : 1920), 1998O, WETTER, P, ERVENICH
+6 more sources